32 Results for "

TGFβ2

" in MedChemExpress (MCE) Product Catalog:
Products (32)

32 Results for "TGFβ2" in MCE Product Catalog:

158
158 Publications Verification
Cat. No.: HY-10087A1
CAS No.: 1093851-28-5
Synonyms: ABT-263 dihydrochloride
Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases [2] .
loading...
    loading...
92
92 Cited Publications
Cat. No.: HY-B0673
CAS No.: 53179-13-8
Synonyms: AMR69
Target:  

TGF-beta/Smad CCR

Research Areas:  

Inflammation/Immunology Cancer

Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-P7119
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFB2; Transforming Growth Factor, Beta 2; Transforming Growth Factor Beta 2; BSC-1 Cell Growth Inhibitor; Glioblastoma-Derived T-Cell Suppressor Factor; TGF-Beta2; Transforming Growth Factor Beta-2 Proprotein; Polyergin; Prepro-Transforming Growth Factor
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99020
CAS No.: 948564-73-6
Synonyms: GC1008

Target:  

TGF-beta/Smad

Research Areas:  

Inflammation/Immunology Cancer

Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease [2] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P70649
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFB2; Transforming Growth Factor, Beta 2; Transforming Growth Factor Beta 2; BSC-1 Cell Growth Inhibitor; Glioblastoma-Derived T-Cell Suppressor Factor; TGF-Beta2; Transforming Growth Factor Beta-2 Proprotein; Polyergin; Prepro-Transforming Growth Factor
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-142118
CAS No.: 925681-61-4
Synonyms: AP 12009
Target:  

TGF-beta/Smad

Research Areas:  

Cancer

Trabedersen (AP 12009) is an orally active synthetic antisense phosphorothioate oligodeoxynucleotide that selectively targets human TGFβ2 mRNA. Trabedersen blocks TGFβ2 protein production, enters the nucleus without a transfection vector, and exerts dose-dependent antitumor effects. By reversing TGFβ2-induced immunosuppression and enhancing immune cytotoxicity, Trabedersen exhibits significant antiproliferative, antimigratory, and antimetastatic activities, with favorable safety profiles. Trabedersen is widely used in research related to various solid tumors, including anaplastic astrocytoma, glioblastoma, colorectal tumor, and melanoma [2] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-142118A
Purity:  92.09%
Synonyms: AP 12009 sodium
Target:  

TGF-beta/Smad

Research Areas:  

Cancer

Trabedersen (AP 12009) sodium is an orally active synthetic antisense phosphorothioate oligodeoxynucleotide that selectively targets human TGFβ2 mRNA. Trabedersen sodium blocks TGFβ2 protein production, enters the nucleus without a transfection vector, and exerts dose-dependent antitumor effects. By reversing TGFβ2-induced immunosuppression and enhancing immune cytotoxicity, Trabedersen sodium exhibits significant antiproliferative, antimigratory, and antimetastatic activities, with favorable safety profiles. Trabedersen sodium is widely used in research related to various solid tumors, including anaplastic astrocytoma, glioblastoma, colorectal tumor, and melanoma [2] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10087S
CAS No.: 1217620-38-6
Purity:  99.71%
Navitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases [2] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700785
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: TGFB2; Transforming Growth Factor, Beta 2; Transforming Growth Factor Beta 2; BSC-1 Cell Growth Inhibitor; Glioblastoma-Derived T-Cell Suppressor Factor; TGF-Beta2; Transforming Growth Factor Beta-2 Proprotein; Polyergin; Prepro-Transforming Growth Factor
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-B0673R
CAS No.: 53179-13-8
Synonyms: AMR69 (Standard)
Pirfenidone (Standard) is the analytical standard of Pirfenidone. This product is intended for research and analytical applications. Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
loading...
    loading...
Cat. No.: HY-B0673S1
CAS No.: 1093951-85-9
Synonyms: LYT-100; AMR69-d3
Deupirfenidone-d3 is the deuterium labeled Pirfenidone (HY-B0673). Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
loading...
    loading...
Cat. No.: HY-B0673S
CAS No.: 1020719-62-3
Synonyms: AMR69-d5
Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
loading...
    loading...
Cat. No.: HY-10087R
CAS No.: 923564-51-6
Synonyms: ABT-263 (Standard)
Navitoclax (Standard) (ABT-263 (Standard)) is the analytical standard of Navitoclax (HY-10087). This product is intended for research and analytical applications. Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases [2] .
loading...
    loading...
Cat. No.: HY-P99695
CAS No.: 285985-06-0
Synonyms: CAT-152

Target:  

TGF-beta/Smad

Research Areas:  

Neurological Disease

Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research [2].
loading...
    loading...
Cat. No.: HY-175205
Target:  

TGF-beta/Smad

Research Areas:  

Cancer

TGF-β2-IN-1 is a selective TGF-β2 inhibitor. TGF-β2-IN-1 exhibits potent antiproliferative effects on HCT-116, Caco-2 and HT-29 with IC50 values of 6.84, 10.21, and 9.47 μM, respectively. TGF-β2-IN-1 inhibits TGF-β2 signaling in a dose-dependent manner by suppressing both receptor and cytokine expression.TGF-β2-IN-1 can be used for the study of colorectal cancer .
loading...
    loading...
Cat. No.: HY-137063
CAS No.: 1409968-46-2
Research Areas:  

Cardiovascular Disease

(+)-ITD-1 is an inhibitor for TGF-β, that inhibits the TGF-β2 with an IC50 of 0.46 μM. (+)-ITD-1 promotes the degradation of TGF-b type II receptor (TGFBR2) and the differentiation of cardiomyocyte, and inhibits the mesoderm formation in the early differentiation stage of mouse embryonic stem cells (mESCs) .
loading...
    loading...
Cat. No.: HY-158821A
Target:  

TGF-beta/Smad

Research Areas:  

Neurological Disease

ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases [2] .
loading...
    loading...
Cat. No.: HY-158821
CAS No.: 2179222-27-4
Target:  

TGF-beta/Smad

Research Areas:  

Neurological Disease

ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases [2] .
loading...
    loading...
Cat. No.: HY-174533
Target:  

mRNA

Research Areas:  

Cancer

Human TGFB2 mRNA encodes the human transforming growth factor beta 2 (TGFB2) protein, a secreted ligand of the TGF-beta superfamily. TGFB2 has suppressive effects on interleukin-2 dependent T-cell growth.
loading...
    loading...
Cat. No.: HY-158821B
Target:  

TGF-beta/Smad

Research Areas:  

Neurological Disease

ISTH0036 sodium scrambled negative control is the sequence scrambled negative control of ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
loading...
    loading...